Wick Capital Partners LLC Sells 4,634 Shares of Astrazeneca Plc $AZN

Wick Capital Partners LLC lowered its holdings in Astrazeneca Plc (NYSE:AZN) by 64.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,571 shares of the company’s stock after selling 4,634 shares during the quarter. Wick Capital Partners LLC’s holdings in Astrazeneca were worth $451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lloyd Advisory Services LLC. bought a new stake in Astrazeneca in the 4th quarter worth about $35,000. Basepoint Wealth LLC purchased a new position in Astrazeneca in the 4th quarter worth about $44,000. Acumen Wealth Advisors LLC bought a new position in Astrazeneca during the 4th quarter valued at about $47,000. Nemes Rush Group LLC lifted its stake in Astrazeneca by 162.1% during the 4th quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock valued at $47,000 after acquiring an additional 167 shares during the period. Finally, South Plains Financial Inc. purchased a new stake in shares of Astrazeneca during the 4th quarter valued at about $50,000. 20.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on AZN. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Trading Down 0.0%

NYSE:AZN opened at $174.87 on Friday. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The business has a fifty day moving average price of $186.62 and a 200-day moving average price of $186.27. The firm has a market capitalization of $271.20 billion, a price-to-earnings ratio of 26.26, a price-to-earnings-growth ratio of 1.52 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Sell-side analysts forecast that Astrazeneca Plc will post 9.39 EPS for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.